ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1218

The Reduction of Serum Uric Acid Level Might Prevent Atherosclerosis in Mice

Yoshitaka Kimura1,2, Tamiko Yanagida3, Akiko Onda4, Hajime Kono2, Maki Takayama2, Kurumi Asako2, Akiko Okamoto2, Hirotoshi Kikuchi2 and Toshihiro Nanki5, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 3Depart ment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 4Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 5Department of Clinical Research Medicine, Teikyo University, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, gout, inflammasome activation and uric acid

  • Tweet
  • Email
  • Print
Session Information

Title: Metabolic and Crystal Arthropathies: Mechanisms of Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Excess amount of uric acid in human body causes acute inflammation, gout. In addition, uric acid is identified as a danger signal and is implicated in playing roles in chronic inflammatory processes. Recently several retrospective studies have reported that serum uric acid might be one of the independent risk factors of atherosclerosis. However there has been no prospective study showing the association of serum uric acid level and atherosclerosis. It’s not still clear whether uric acid progresses atherosclerosis. Using the transgenic mice expressed uricase, anuric acid hydrolytic enzyme, we investigated the reduction of serum uric acid level could prevent atherosclerosis in mice.

Methods:

We prepared uricase transgenic mice based in C57BL/6 mice. They expressed the urcase secreted to extracellular space and their serum uric acid level were decreased. We bred UricaseTg mice with LDL receptor deficient or apolipoprotein E deficient mice to develop LDLR-/-UricaseTg mice or ApoE-/-UricaseTg mice, respectively. LDLR-/-UricaseTg mice, ApoE-/-UricaseTg mice and control mice (LDLR-/- mice and ApoE-/-mice) at 6 weeks of age received high-fat diet for 16 weeks. Then their hearts and aortas were removed at 22 weeks of age. Aortic sinuses of these mice were fixed and sliced into 8 micrometer. We measured atherosclerosis area of each slice and computed volume of lesions of aortic sinus. Aortas of these mice were stained with oil red O and measured area of atherosclerosis lesions. We calculated ratio of the lesion area to whole aortic area.

Results:

The volumes of atherosclerosis lesions in aortic sinuses of LDLR-/-UricaseTg (0.158±0.016 mm3) [n=17] were smaller than that of LDLR-/- (0.231±0.017 mm3) [n=12] [p=0.0049]. There were no significant differences between ApoE-/-UricaseTg (0.227±0.022 mm3) [n=15] and ApoE-/- (0.292±0.032 mm3) [n=7] [p=0.11]. The ratio of area of atherosclerosis in aorta was 7.4±1.2 % in LDLR-/-UricaseTg [n=14], 8.1±0.9% in LDLR-/- [n=24], 6.0±0.8% in ApoE-/-UricaseTg [n=15] and 5.3±0.6% in ApoE-/- [n=7]. There were little differences between each group (LDLR-/-UricaseTg vs LDLR-/-UricaseTg [p=0.63], ApoE-/-UricaseTg vs ApoE-/-[p=0.63]).

Conclusion:

Although there was a discrepancy between atherosclerosis prone strains, the results showed that the reduction of serum uric acid level by expressing secretable uriasemay inhibit the progression of atherosclerosis.



Disclosure:

Y. Kimura,
None;

T. Yanagida,
None;

A. Onda,
None;

H. Kono,
None;

M. Takayama,
None;

K. Asako,
None;

A. Okamoto,
None;

H. Kikuchi,
None;

T. Nanki,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-reduction-of-serum-uric-acid-level-might-prevent-atherosclerosis-in-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology